Search results
Showing 8491 to 8505 of 8908 results
Ventripoint Medical System Plus for measuring heart volume and function (MIB310)
February 2023: The medtech innovation briefing on Ventripoint Medical System Plus for measuring heart volume and function has been withdrawn as the company have withdrawn from the process.
QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)
This advice has been updated and replaced by NICE healthtech guidance 729.
BPMpathway for rehabilitation support in joint replacement surgery (MIB319)
MIB319 BPMpathway for rehabilitation support in joint replacement surgery has been withdrawn. This is because factual inaccuracies have been identified. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, therefore these are no longer being reviewed.
Flow transcranial direct current stimulation for treating depression (MIB324)
May 2024: This medtech innovation briefing has been withdrawn. This is because the evidence for the technology has changed since it was published. NHS England no longer funds NICE to produce or maintain medtech innovation briefings, so these are no longer being reviewed.
This advice has been updated and replaced by NICE medical technologies guidance 47.
AliveCor Heart Monitor and AliveECG app (Kardia Mobile) for detecting atrial fibrillation (MIB35)
This advice has been updated and replaced by NICE medtech innovation briefing 232.
The BCM – Body Composition Monitor for managing fluid in people having dialysis (MIB41)
This advice has been updated and replaced by NICE guidance HTG441
EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)
This advice has been updated and replaced by NICE diagnostics guidance 34.
PneuX for preventing ventilator-associated pneumonia in intensive care (MIB45)
This advice has been updated and replaced by NICE medical technologies guidance 48.
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued Reference number: GID-HST10038
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
Discontinued Reference number: GID-HST10004
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.
COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.